Human immunodeficiency virus type 1 (HIV-1)-seropositive homosexuals and narcotic addicts develop a newly described syndrome of immunologic thrombocytopenic purpura (ITP) (1, 2) that is clinically indistinguishable from the classic autoimmune thrombocytopenic purpura (ATP) seen predominantly in females (3) . However, their platelets have markedly elevated IgG, IgM, and C3C4 (2, 4) compared to classic ATP patients and their sera contain elevated immune complexes determined by the polyethylene glycol (PEG) method, whereas ATP patients' sera do not (2, 4) . In addition, many of the HIV-1-seropositive thrombocytopenic patients have anti-F(ab')2 antibodies that correlate with their circulating immune complex level (5) . It has been proposed that the elevated IgG and C3C4 on their platelets may represent deposition of immune complexes and that this may in part or in whole be responsible for the pathophysiology of the thrombocytopenia (4) .
The purpose of this investigation was to determine whether HIV-1 antibody and/or HIV-1 virus is present on these platelets and, if so, whether they exist as a complex. A preliminary report of the investigation has appeared (6) . METHODS
Population. The population studied consisted of 36 HIV-1-seropositive patients with ITP: 15 homosexuals (HSITP) and 21 narcotic addicts (NITP); 10 asymptomatic HIV-1-seropositive subjects with normal hemograms, consisting of 5 homosexuals and 5 narcotic addicts; 15 classic ATP patients; and 14 healthy control subjects.
Non-HIV Viral Antibody. Viral antibody studies were performed for Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), adenoviruses (ADE), and varicella-zoster virus (VZV) by standard immunofluorescent techniques (7) .
HIV-1 Antibody. HIV-1 antibody was detected by a solidphase absorption, ELISA assay employing the Abbott kit, in which the developing antibody was an anti-human IgG coupled to alkaline phosphatase, as well as by an immunoblot procedure employing antigen-nitrocellulose strips supplied by Epitope (Beaverton, OR), in which the developing antibody was an anti-human IgG (H + L) coupled to horseradish peroxidase.
HIV-1 Antigen. HIV-1 antigen was detected by an antigen capture assay kit employing human polyclonal antibodies supplied by Cellular Products (Buffalo, NY) (8) .
Platelet-Rich Plasma. Platelet-rich plasma was prepared from EDTA/anticoagulated blood as described (9) and was either further processed by centrifugation and washing as described (9) for elution and binding experiments or placed on a Sepharose 2B gel-filtration column (Pharmacia) for DNA extraction. The gel-filtration procedure was employed to prepare platelets entirely free of lymphocytes.
Peripheral Blood Mononuclear Cells (PBMCs). PBMCs were prepared from fresh heparinized blood using leukocyte separation medium (Organon Teknika).
HIV-1 Proviral DNA Gene Amplification. The polymerase chain reaction (PCR) method (8, (10) (11) (12) was employed to test for the presence of HIV-1 proviral DNA and human p-globin DNA sequences in PBMCs and platelets of eight HIV-1-seropositive patients with immunologic thrombocytopenia to determine whether either or both cell types were infected in vivo and to establish the purity of the platelet preparations. PBMCs were lysed in a sodium dodecyl sulfate (SDS)/ proteinase K solution and incubated overnight; DNA was isolated by phenol and chloroform/isoamyl alcohol extraction followed by alcohol precipitation (13) . Platelets, devoid of lymphocytes, were similarly treated to precipitate any nonintegrated HIV-1 DNA and mitochondrial DNA that may have been present in these preparations. DNA concentrations were estimated from 260/280-nm absorption.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Platelet Eluates. Platelet eluates were prepared by acid elution (16) . Briefly, 1 x 108 washed platelets (9) were suspended in 200 ,ul of a modified human Ringer's solution (9) and acidified by addition of 100 ,u of 150 mM H3PO4/100 mM NaCl/1.5% bovine serum albumin, pH 2.8, for 10 min, with shaking at 37°C. In some experiments, the platelet suspension was frozen and thawed three times with dry ice/ethanol prior to acidification with similar results. The acidified suspension was centrifuged at 20,000 x g and neutralized with 2.5 M Tris to pH 8.0. Eluted IgG was assayed by immunoassay as described (17) .
Platelet Extracts. Platelet extracts were prepared from washed platelets suspended in 1% Triton X-100/0.15 M NaCl/0.01 M Tris buffer, pH 7.4, at a platelet concentration of 5 x 108 per ml, :1 mg/ml. The suspension was dispersed in a Vortex and centrifuged at 15,000 x g for 3 min, and the supernatant was employed for assay.
Immune Complexes. Immune complexes were prepared from serum by PEG precipitation (5). Precipitates were dissolved in one-fifth the usual volume for platelet incubation experiments (=2-4 mg/ml).
Purified IgG. Purified IgG was prepared by ion-exchange chromatography (5).
Gel Filtration. Gel filtration was performed on Sephadex G-200 as described (4) . Fractions were concentrated 10-fold employing a B15 Amicon microconcentrator prior to incubation with platelets (==1 mg/ml).
Binding of Anti-HIV-1 Immune Complexes and/or 7S IgG to Washed Platelets. Washed normal platelets (6 x 108) were incubated with PEG precipitate (2-4 mg/ml), void volume, or 7S IgG fraction (1-2 mg/ml) in a volume of 400 ,ul in phosphate-buffered saline (PBS) for 3 hr at room temperature; this was followed by overnight incubations at 4°C. The 400-,lI suspension was then applied to 4 ml of a 20% sucrose cushion centrifuged at 12,350 x g for 10 min at 4°C to separate bound from unbound ligand. The sucrose was removed and the platelet pellet was eluted with acid, as above.
Affinity-Purified Anti-HIV-1. Affinity-purified anti-HIV-1 was prepared by adsorption of purified IgG to Affi-Gel 10 coupled to recombinant gpl20 of the HIV-1 envelope glycoprotein. Anti-Anti-HIV-1 Antibody. Anti-anti-HIV-1 antibody was prepared by coupling affinity-purified anti-HIV-1 antibody (0.6 mg) to an Affi-Gel 10 column. Purified IgG from 1 ml of patients' sera was adsorbed, washed, and eluted as above.
One milliliter provided =20 ,ug of anti-anti-HIV-1 antibody.
Anti-anti-HIV-1 antibody was also prepared from platelet eluates by a strategy described for anti-F(ab')2 antibodies (5) . Briefly, the anti-HIV-i Affi-Gel affinity column was acidified to pH 2.5 with 0.1 M glycine buffer mixed with platelet eluates similarly acidified, and the slurry was slowly neutralized by dialysis overnight against PBS/0.02% azide. By this method the solid-phase anti-HIV-1 antibody competes with the dissociated anti-anti-HIV-1 antibody of the acid platelet eluate as the pH is raised. The Affi-Gel matrix was then washed and eluted as above. Affinity-purified anti-gpl20 antibody was employed to construct a standard curve of anti-HIV-1 OD vs. IgG protein concentration, which was linear with a logarithmic-logarithmic plot. Regression analysis revealed a correlation coefficient of r = 0.86, P < 0.001. The specific activity of three different affinity-purified preparations averaged 0.050 OD per ng of IgG. Eluted platelet IgG from patients' platelets was then estimated for percentage of anti-HIV-1 activity. This represented 50% ± 16% for four HSITP patients and 61% ± 3% for four NITP patients. Their serum percent anti-HIV of total serum IgG was 12% ± 5% and 37% ± 4%, respectively. These measurements are based on the assumption that the avidity of other anti-HIV-1 antibodies is not appreciably different from that of anti-gpl20. It is supported by the observation that anti-gpl20 represents 40% ± 6.4% of total platelet anti-HIV-1 antibody, as determined from the relative binding of platelet eluate IgG to gpl20 and virus-absorbed beads (three experiments).
RESULTS

Non
Gel Filtration of Platelet Eluates and Serum Immune Complexes Containing Anti-HIV-1 Antibody. Fig. 2 demonstrates the presence of anti-HIV-1 antibody in the void volume fraction of platelet eluates of HSITP and NITP patients following gel filtration, indicating the presence of anti-HIV-1 antibody as a complex. Thus, neutralization of the acid eluate was sufficient to reassociate any complexes that may have dissociated during this procedure, or the complexes may not have dissociated under these conditions. No anti-HIV-1 activity was demonstrable in the 7S region. Similar results were obtained with two other gel filtrations of HSITP as well as NITP patients (data not shown).
Similar results were obtained with the immune complexes of three HSITP as well as three NITP patients (data not shown).
Binding of Anti-HIV-1 Antibody of PEG-Precipitable Immune Complexes, Void Volume, and 7S IgG Fractions and Affinity-Purified Anti-HIV-1 Antibody to Platelets. Anti-HIV-1 antibody of PEG-precipitable immune complexes bound to washed normal platelets by saturation-dependent kinetics employing eluted anti-HIV-1 ELISA OD readings as end point (data not shown). PEG-precipitable material containing anti-HIV-1 antibody from four HSITP patients bound to 6 x 108 normal platelets with HIV-1 OD values of 0.65 ± 0.17 and 0.83 ± 0.38, respectively, at saturation, whereas six control or six ATP PEG precipitates bound with a HIV-1 OD (Fig. 3) . Only one patient's amplified platelet DNA sample DNA control. Patients A3-4, A5-6, Bl-2, and B3-4 were gave indication of HIV-1 sequences. This sample was, howfor proviral DNA in their PBMCs but were negative in their ever, also positive after gene amplification initiated by s. Patient Al-2 was HIV-l-positive in PBMCs as well as in sequences corresponding to the human P-globin gene. The s. Hlowever, the "platelet" sample was positive for human ratio of HIV-1 to f-globin signals obtained following PCR i gene as well, indicating that human genomic DNA was appeared to be about the same from platelet and PBMC due to contamination with nucleated cells. due to contamination with nucleated cells.
preparations (data not shown). Other patient platelet samples )f 0.03 ± 0.01. Table 2 demonstrates the binding of were PCR negative for the globin region, indicating their high IV-1 antibody from gel-filtration fractions of PEG-predegree of punty. DISCUSSION HIV-1-seropositive ITP in homosexuals and narcotic addicts is different from classic ATP in that the platelet surface has markedly elevated IgG, C3C4, and IgM (2, 4). Platelet-bound IgG and C3C4 are 3-to 4-fold greater; platelet-bound IgM is 2-to 3-fold greater. In addition, PEG-precipitable serum immune complex levels in the HIV-1-seropositive thrombocytopenic patients are 3-to 7-fold greater than normal and are not elevated in classic ATP patients (2, 4) . Thus an attractive explanation for the marked deposition of immunoglobulin and complement on these platelets is the deposition of these circulating immune complexes on platelets, presumably on their Fc receptors. This prompted a careful analysis of the content of their circulating immune complexes as well as platelet membrane eluates. We have recently (5) noted that their PEG-precipitable immune complexes contain numerous antibodies against various viral antigens to which they have been exposed (EBV, CMV, HSV, rubeola virus); however, viral antigen was not found. This suggested the possibility of complexes composed of antibody directed against antibody. Further experiments demonstrated the presence of anti-F(ab')2 antibodies in their sera and immune complexes as well as in their platelet eluates (5) .
The present report demonstrates the presence of anti-HIV-1 antibody as well as anti-anti-HIV-1 antibody in their serum immune complexes as well as in their platelet eluates. These data support our previous observation on the presence of anti-F(ab')2 antibodies in their serum immune complexes as well as platelet eluates (5). HIV-1 was not found in the platelet eluates or platelet extracts, as determined by an antigen capture technique. Nor was HIV-1 proviral DNA found in the purified platelets themselves, as tested by a gene amplification technique. The latter technique is extremely sensitive for detecting human retroviral sequences present in low copy numbers (10, 12) . The concentration of anti-HIV-1 in these eluates was determined from a standard curve prepared from affinity-purified anti-HIV-i (gpi20). This revealed very high concentrations of anti-HIV-i antibody on platelets, averaging 50% of total platelet IgG. This observation is supported by the positive correlation between platelet eluate IgG and eluted anti-HIV-1 concentration. In addition, other anti-viral antibodies, such as anti-EBV (VCA), CMV, and HSV, were not found in their platelet eluates despite their presence in sera of these patients. Thus the platelet appears to be a reservoir for the deposition of anti-HIV-1 immune complexes composed of anti-anti-HIV-1 as well as anti-HIV-1 antibodies. This is further supported by our inability to demonstrate cross-reactivity between anti-HIV-1 antibody and the platelet membrane. The explanation for this apparent preference of anti-HIV-1 complexes on platelets has not been determined. It is possible that the anti-HIV-1 antibody complexes may be present in greater concentration than other viral antibody complexes. Alternatively, the physical structure of the anti-HIV-1 complexes may have greater affinity for the platelet than other viral complexes. The stoichiometry of the anti-HIV-1 complexes could not be accurately determined. However, it was of interest that the yield of anti-anti-HIV-1 antibody from serum was -5-i0% of the yield of anti-HIV-1 antibody.
We (18) .
